In choosing Hikma v. Amarin, the Court has focused on a narrow question aligned with current concerns about drug pricing—while leaving unresolved deeper uncertainties in patent law that affect innovation across the entire economy.

Drawing on Austrian economics, CFJ argues that market prices—not foreign administrative ceilings—guide rational investment and innovation. Embedding government-set international price controls into Medicare would distort those signals and undermine U.S. pharmaceutical leadership

CMS’s GLOBE and GUARD proposals would tie Medicare drug payments to foreign government-set prices. In its comments, CFJ warns that importing international reference pricing into Medicare risks distorting innovation incentives and layering additional complexity onto an already heavily regulated system.